文献速递神经儿科影像MR

司美替尼治疗儿童低级别胶质瘤的ADC直方图分析:儿童脑肿瘤联盟报告

ADC Histogram Analysis of Pediatric Low-Grade Glioma Treated with Selumetinib: A Report from the Pediatric Brain Tumor Consortium.
PubMed 文献 · AJNR Am J Neuroradiol · 2022-02-24

本研究纳入复发、难治或进展性儿童低级别胶质瘤患者,按KIAA1549-BRAF融合或BRAF V600E突变(第1层)、1型神经纤维瘤病相关(第3层)、散发性非1型神经纤维瘤病视路和下丘脑胶质瘤(第4层)分层,每层25例,接受司美替尼治疗最长2年。分析基线与治疗期间ADC直方图指标,发现ADC_total直方图参数与无进展生存期及治疗反应相关。

要点

  • 第1层应答者基线ADC_total标准差较低,且治疗中ADC_total均值、众数和中位数下降幅度大于无应答者。
  • 第4层基线ADC_total偏度和峰度较高与无进展生存期较短相关。
  • 1型神经纤维瘤病相关视路和下丘脑胶质瘤基线ADC_total均值、众数和中位数低于散发性,偏度和峰度更高。

核心结论

  • ADC直方图指标与儿童低级别胶质瘤司美替尼治疗的无进展生存期和治疗反应相关。

研究设计与样本

  • 儿童脑肿瘤联盟报告,纳入复发、难治或进展性儿童低级别胶质瘤患者,分3层(第1层:WHO I级毛细胞星形细胞瘤伴KIAA1549-BRAF融合或BRAF V600E突变;第3层:1型神经纤维瘤病相关;第4层:散发性非1型神经纤维瘤病视路和下丘脑胶质瘤),每层25例,司美替尼治疗最长2年,分析基线与治疗期间全肿瘤和强化肿瘤体积的定量ADC直方图指标。

诊断标准与关键数值

  • 第1层应答者基线ADC_total标准差低于无应答者,治疗中ADC_total均值、众数和中位数下降幅度大于无应答者。
  • 第3层应答者ADC_total纵向下降幅度大于无应答者。
  • 第4层基线ADC_total偏度和峰度较高与无进展生存期较短相关。
  • 3层合并后,应答者治疗中ADC_total众数和中位数下降幅度大于无应答者。
  • 与散发性视路和下丘脑胶质瘤相比,1型神经纤维瘤病相关者基线ADC_total均值、众数和中位数及ADC_enhancement均值和中位数较低,ADC_total偏度和峰度较高。

临床应用与阅片要点

  • ADC直方图指标(包括ADC_total标准差、均值、众数、中位数、偏度和峰度)可能有助于评估儿童低级别胶质瘤司美替尼治疗的反应和预后。
  • 基线ADC_total偏度和峰度较高可能提示1型神经纤维瘤病相关视路和下丘脑胶质瘤无进展生存期较短。
  • 1型神经纤维瘤病相关与散发性视路和下丘脑胶质瘤的基线ADC直方图特征不同,阅片时可结合病因背景解读。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: Selumetinib is a promising MAP (mitogen-activated protein) kinase (MEK) 1/2 inhibitor treatment for pediatric low-grade gliomas. We hypothesized that MR imaging-derived ADC histogram metrics would be associated with survival and response to treatment with selumetinib.

MATERIALS AND METHODS: Children with recurrent, refractory, or progressive pediatric low-grade gliomas who had World Health Organization grade I pilocytic astrocytoma with KIAA1549-BRAF fusion or the BRAF V600E mutation (stratum 1), neurofibromatosis type 1-associated pediatric low-grade gliomas (stratum 3), or sporadic non-neurofibromatosis type 1 optic pathway and hypothalamic glioma (OPHG) (stratum 4) were treated with selumetinib for up to 2 years. Quantitative ADC histogram metrics were analyzed for total and enhancing tumor volumes at baseline and during treatment.

RESULTS: Each stratum comprised 25 patients. Stratum 1 responders showed lower values of SD of baseline ADC_total as well as a larger decrease with time on treatment in ADC_total mean, mode, and median compared with nonresponders. Stratum 3 responders showed a greater longitudinal decrease in ADC_total. In stratum 4, higher baseline ADC_total skewness and kurtosis were associated with shorter progression-free survival. When all 3 strata were combined, responders showed a greater decrease with time in ADC_total mode and median. Compared with sporadic OPHG, neurofibromatosis type 1-associated OPHG had lower values of ADC_total mean, mode, and median as well as ADC_enhancement mean and median and higher values of ADC_total skewness and kurtosis at baseline. The longitudinal decrease in ADC_total median during treatment was significantly greater in sporadic OPHG compared with neurofibromatosis type 1-associated OPHG.

CONCLUSIONS: ADC histogram metrics are associated with progression-free survival and response to treatment with selumetinib in pediatric low-grade gliomas.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Vajapeyam, Brown, Ziaei, et al. ADC Histogram Analysis of Pediatric Low-Grade Glioma Treated with Selumetinib: A Report from the Pediatric Brain Tumor Consortium. AJNR Am J Neuroradiol. 2022. PMID: 35210278. doi:10.3174/ajnr.A7433

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。